JP7824627B2 - 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物 - Google Patents

癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Info

Publication number
JP7824627B2
JP7824627B2 JP2021557187A JP2021557187A JP7824627B2 JP 7824627 B2 JP7824627 B2 JP 7824627B2 JP 2021557187 A JP2021557187 A JP 2021557187A JP 2021557187 A JP2021557187 A JP 2021557187A JP 7824627 B2 JP7824627 B2 JP 7824627B2
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
pharmaceutically acceptable
iadademstat
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526525A (ja
JP2022526525A5 (cg-RX-API-DMAC10.html
Inventor
シセリ フィリッポ
Original Assignee
オリソン ヘノミクス,ソシエダ アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリソン ヘノミクス,ソシエダ アノニマ filed Critical オリソン ヘノミクス,ソシエダ アノニマ
Publication of JP2022526525A publication Critical patent/JP2022526525A/ja
Publication of JP2022526525A5 publication Critical patent/JP2022526525A5/ja
Priority to JP2026021790A priority Critical patent/JP2026077769A/ja
Application granted granted Critical
Publication of JP7824627B2 publication Critical patent/JP7824627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021557187A 2019-03-25 2020-03-25 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物 Active JP7824627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026021790A JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
EP19382206.1 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026021790A Division JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Publications (3)

Publication Number Publication Date
JP2022526525A JP2022526525A (ja) 2022-05-25
JP2022526525A5 JP2022526525A5 (cg-RX-API-DMAC10.html) 2023-04-04
JP7824627B2 true JP7824627B2 (ja) 2026-03-05

Family

ID=66175363

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557187A Active JP7824627B2 (ja) 2019-03-25 2020-03-25 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
JP2026021790A Withdrawn JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026021790A Withdrawn JP2026077769A (ja) 2019-03-25 2026-02-13 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC10.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC10.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210142614A (cg-RX-API-DMAC10.html)
CN (2) CN113573702A (cg-RX-API-DMAC10.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC10.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC10.html)
IL (1) IL286353A (cg-RX-API-DMAC10.html)
MX (1) MX2021011610A (cg-RX-API-DMAC10.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC10.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP2018516883A (ja) 2015-05-06 2018-06-28 オリソン ヘノミクス エセ. アー. 固体形態

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US20190256929A1 (en) * 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018516883A (ja) 2015-05-06 2018-06-28 オリソン ヘノミクス エセ. アー. 固体形態
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cell,2018年,174,pp.549-563
Journal of Clinical Oncology,2019年05月,Vol. 37, Supplement 15,Abstract Number: e14248,DOI: 10.1200/jco.2019.37.15_suppl.e14248

Also Published As

Publication number Publication date
CN113573702A (zh) 2021-10-29
SG11202109025XA (en) 2021-09-29
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
BR112021016171A2 (pt) 2021-10-05
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
AU2020249493B2 (en) 2025-08-28
IL286353A (en) 2021-10-31
MX2021011610A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
JP2019517549A5 (cg-RX-API-DMAC10.html)
JP2026077769A (ja) 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物
HU226672B1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers
RU2006120950A (ru) Антитело к cd40: препарат и способы
WO2015085289A1 (en) Combination of aurora kinase inhibitors and anti-cd30 antibodies
TW202406544A (zh) 哌類化合物和pd-1抑制劑或pd-l1抑制劑的組合物以及其在製備抗腫瘤藥物中的用途
KR20200083532A (ko) 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
WO2017205216A1 (en) Combination of pembrolizumab and abemaciclib for the treatment of cancer
IL316182A (en) Combination therapy preparations based on PD1 inhibitors and SIK3 inhibitors
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JP2017515843A (ja) 抗egfr治療薬の投与量および投与
JP2022547061A5 (cg-RX-API-DMAC10.html)
RU2833564C2 (ru) Комбинации иададемстата для лечения рака
AU2020228385A1 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
CN100553634C (zh) 用于治疗多发性骨髓瘤的埃坡霉素衍生物
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
CN114667159B (zh) 喹啉衍生物与pd-1单抗的药物组合
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
CN118436642A (zh) 干扰肿瘤Treg细胞分化的药物及其应用
WO2026074499A1 (en) Methods and compositions for inhibiting c-myc

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7824627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150